Artivion, Inc. AORT
We take great care to ensure that the data presented and summarized in this overview for ARTIVION, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AORT
View all-
Black Rock Inc. New York, NY6.64MShares$189 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.8MShares$80 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY2.79MShares$79.8 Million1.94% of portfolio
-
Macquarie Group LTD Australia, C32.75MShares$78.4 Million0.08% of portfolio
-
Morgan Stanley New York, NY2.45MShares$70 Million0.0% of portfolio
-
Juniper Investment Company, LLC New York, NY2.1MShares$59.9 Million22.69% of portfolio
-
Wellington Management Group LLP Boston, MA1.66MShares$47.3 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.54MShares$44 Million0.01% of portfolio
-
State Street Corp Boston, MA1.51MShares$43.2 Million0.0% of portfolio
-
Gw&K Investment Management, LLC Boston, MA1.14MShares$32.4 Million0.26% of portfolio
Latest Institutional Activity in AORT
Top Purchases
Top Sells
About AORT
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Insider Transactions at AORT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 12
2024
|
Amy Horton VP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
1,100
-0.81%
|
-
|
Dec 11
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
8,070
-2.52%
|
$242,100
$30.13 P/Share
|
Dec 06
2024
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,329
-3.09%
|
$125,541
$29.66 P/Share
|
Dec 04
2024
|
Andrew M Green VP Regulatory |
SELL
Open market or private sale
|
Direct |
7,618
-18.53%
|
$228,540
$30.0 P/Share
|
Oct 01
2024
|
Amy Horton VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,430
-8.16%
|
$323,180
$26.18 P/Share
|
Oct 01
2024
|
Amy Horton VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,430
+7.54%
|
$261,030
$21.55 P/Share
|
Aug 26
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
3,167
-1.92%
|
$82,342
$26.55 P/Share
|
Aug 16
2024
|
Matthew A Getz VP, Human Resources |
SELL
Open market or private sale
|
Direct |
9,420
-11.37%
|
$235,500
$25.31 P/Share
|
Aug 15
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,383
-1.42%
|
$59,575
$25.76 P/Share
|
Aug 13
2024
|
Anthony B. Semedo Director |
SELL
Open market or private sale
|
Direct |
9,709
-22.13%
|
$233,016
$24.99 P/Share
|
May 30
2024
|
Daniel J Bevevino Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,289
+4.19%
|
-
|
May 30
2024
|
Thomas F Ackerman Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,289
+4.2%
|
-
|
May 30
2024
|
James Bullock Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,289
+9.17%
|
-
|
May 30
2024
|
Jon W Salveson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,289
+4.85%
|
-
|
May 30
2024
|
Marna P Borgstrom Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,289
+12.82%
|
-
|
May 30
2024
|
Jeffrey H Burbank Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,289
+11.7%
|
-
|
May 30
2024
|
Anthony B. Semedo Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,289
+12.54%
|
-
|
May 30
2024
|
Elizabeth A Hoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,289
+20.06%
|
-
|
May 10
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,250
-0.74%
|
$28,750
$23.42 P/Share
|
May 09
2024
|
Jean F Holloway SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
979
-0.58%
|
$22,517
$23.79 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 533K shares |
---|---|
Exercise of conversion of derivative security | 106K shares |
Open market or private sale | 273K shares |
---|---|
Bona fide gift | 1.1K shares |